728x90 the wearable artificial kidney1 이오플로우, EOFlow Issues Convertible Bonds Worth 35 Billion Korean Won EOFlow Issues Convertible Bonds Worth 35 Billion Korean Won...Raised Capital Will be Used on Clinical Trials, R&D and Investment in New Businesses ▶ EOFlow aims to develop clinical studies and R&D of wearable artificial pancreas (AP), develop R&D and investments in new wearable drug delivery solutions ▶ EOFlow secures mid- to long-term growth momentum based on the innovative EOPatch platform tec.. 2021. 1. 20. 이전 1 다음 320x100
